<p>随着全球市场应对贸易政策的复杂性和波动的通货膨胀率，美国股市展现出韧性，主要指数显著上涨，尽管在周末出现了一些抛售压力。在这种环境下，内部持股比例高的成长型公司因其管理层与股东之间的利益一致性而显得尤为突出，这在持续的经济不确定性中可能带来特别的优势。</p>
<h3>全球内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>上海华测导航技术（深交所：300627）</td>
<td>24.5%</td>
<td>23.4%</td>
</tr>
<tr>
<td>富林精密（深交所：300432）</td>
<td>13.6%</td>
<td>44.2%</td>
</tr>
<tr>
<td>KebNi（OM:KEBNI B）</td>
<td>38.3%</td>
<td>67%</td>
</tr>
<tr>
<td>Pharma Mar（BME:PHM）</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>老普金（港交所：6181）</td>
<td>35.5%</td>
<td>40.6%</td>
</tr>
<tr>
<td>浙江零跑科技（港交所：9863）</td>
<td>15.6%</td>
<td>60.1%</td>
</tr>
<tr>
<td>Vuno（KOSDAQ:A338220）</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>苏州三门科技（深交所：300522）</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories（OB:ELABS）</td>
<td>22.9%</td>
<td>79%</td>
</tr>
<tr>
<td>Techwing（KOSDAQ:A089030）</td>
<td>18.8%</td>
<td>68%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们内部持股比例高的 840 只快速成长全球公司的完整名单。</p>
<p>在这里，我们重点介绍我们独家筛选器中的几家最爱。</p>
<h2>3Peak（上交所：688536）</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 3Peak Incorporated 专注于模拟集成电路产品的研发和销售，业务覆盖中国及国际市场，市值为 190.6 亿人民币。</p>
<p><strong>运营：</strong> 公司在集成电路行业的运营收入为 14.4 亿人民币。</p>
<p><strong>内部持股比例：</strong> 14.2%</p>
<p><strong>收入增长预测：</strong> 年均 26.6%。</p>
<p>3Peak 的收入预计将显著增长，年均增长 26.6%，超过中国市场的平均增长率。公司最近报告了扭亏为盈，2025 年第一季度净收入为 1556 万人民币，而去年则出现亏损。尽管其股价波动性较高，且预计股本回报率较低，但预计将在三年内实现盈利，反映出在稳定的内部持股动态下强劲的增长潜力。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解 3Peak 的表现。</li>
<li>我们的估值报告揭示了 3Peak 的股票可能以溢价交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth"/></p>
<p>上交所：688536 截至 2025 年 6 月的收益和收入增长</p>
<h2>奇安信科技集团（上交所：688561）</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 奇安信科技集团有限公司是一家网络安全公司，向中国及国际的政府、企业和其他机构提供产品和服务，市值为 205.8 亿人民币。</p>
<p><strong>运营：</strong> 公司在信息安全行业的收入为 43.3 亿人民币。</p>
<p><strong>内部持股比例：</strong> 22%</p>
<p><strong>收入增长预测：</strong> 年均 19.3%。</p>
<p>奇安信科技集团有望实现增长，预计收入年均增长 19.3%，超过中国市场的平均水平。尽管 2025 年第一季度净亏损为 4.1768 亿人民币，但预计公司将在三年内实现盈利，显示出强劲的增长潜力。其股票以显著折扣交易于估计公允价值，并且最近宣布了一项 3 亿人民币的私募配售，待股东批准，这表明在稳定的内部持股下进行战略财务操作。</p>
<ul>
<li>点击这里了解奇安信科技集团的细微差别，查看我们的详细分析未来增长报告。</li>
<li>根据我们最近的估值报告，奇安信科技集团的股票似乎低于其估计价值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown"/></p>
<p>上交所：688561 截至 2025 年 6 月的持股结构</p>
<h2>浙江佐力药业（深交所：300181）</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 浙江佐力药业有限公司从事中药产品的研发、生产和营销，业务覆盖国内外，市值为 111.1 亿人民币。</p>
<p><strong>运营：</strong> 浙江佐力药业有限公司主要通过中药产品的研发、生产和营销在国内外市场产生收入。</p>
<p><strong>内部持股比例：</strong> 23.1%</p>
<p><strong>收入增长预测：</strong> 年均 20.4%。</p>
<p>浙江佐力药业显示出良好的增长前景，预计收入年均增长 20.4%，超过中国市场。尽管其 3.38% 的股息收益率未完全由自由现金流覆盖，但与同行相比，该公司以良好的价值交易，且价格显著低于其估计公允价值。最近的财报显示出强劲的财务表现，销售和净收入同比增长，而内部持股保持稳定，近期没有重大交易活动。</p>
<ul>
<li>点击以探索我们在浙江佐力药业收益增长报告中的详细发现。</li>
<li>我们的浙江佐力药业估值报告中的分析暗示其股价相较于估计价值被低估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth"/></p>
<p>深交所：300181 截至 2025 年 6 月的收益和收入增长</p>
<h2>接下来该如何？</h2>
<ul>
<li>点击这里访问我们 840 家快速成长全球公司内部持股比例高的完整索引。</li>
<li>寻找其他投资？发现 19 家在 COVID 后生存并蓬勃发展的公司，具备应对特朗普关税的正确条件。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

佐力药业

<p>在 2025 年 6 月，美国股市在贸易政策复杂性和通货膨胀波动中表现出韧性，高内部持股的成长型公司成为强有力的投资选择。值得注意的公司包括 3Peak、奇安信科技集团和浙江佐力药业，这些公司都展现出显著的收入增长预测和稳定的内部持股。尽管其中一些公司面临净亏损，但预计在三年内将实现盈利，显示出强劲的增长潜力。文章强调了管理层与股东之间利益的一致性作为在不确定经济条件下的关键优势</p>

<p>As global markets navigate the complexities of trade policies and fluctuating inflation rates, U.S. stocks have shown resilience with notable gains in major indices, despite some late-week selling pressures. In this environment, growth companies with high insider ownership stand out as potentially robust investments due to their alignment of interests between management and shareholders, which can be especially advantageous amidst ongoing economic uncertainties.</p>
<div class="lb-trans"><p>随着全球市场应对贸易政策的复杂性和波动的通货膨胀率，美国股市展现出韧性，主要指数显著上涨，尽管在周末出现了一些抛售压力。在这种环境下，内部持股比例高的成长型公司因其管理层与股东之间的利益一致性而显得尤为突出，这在持续的经济不确定性中可能带来特别的优势。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology (SZSE:300627)</td>
<td>24.5%</td>
<td>23.4%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>44.2%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>67%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>40.6%</td>
</tr>
<tr>
<td>Zhejiang Leapmotor Technology (SEHK:9863)</td>
<td>15.6%</td>
<td>60.1%</td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Suzhou Sunmun Technology (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>22.9%</td>
<td>79%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>18.8%</td>
<td>68%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>上海华测导航技术（深交所：300627）</td>
<td>24.5%</td>
<td>23.4%</td>
</tr>
<tr>
<td>富林精密（深交所：300432）</td>
<td>13.6%</td>
<td>44.2%</td>
</tr>
<tr>
<td>KebNi（OM:KEBNI B）</td>
<td>38.3%</td>
<td>67%</td>
</tr>
<tr>
<td>Pharma Mar（BME:PHM）</td>
<td>11.8%</td>
<td>43.1%</td>
</tr>
<tr>
<td>老普金（港交所：6181）</td>
<td>35.5%</td>
<td>40.6%</td>
</tr>
<tr>
<td>浙江零跑科技（港交所：9863）</td>
<td>15.6%</td>
<td>60.1%</td>
</tr>
<tr>
<td>Vuno（KOSDAQ:A338220）</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>苏州三门科技（深交所：300522）</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories（OB:ELABS）</td>
<td>22.9%</td>
<td>79%</td>
</tr>
<tr>
<td>Techwing（KOSDAQ:A089030）</td>
<td>18.8%</td>
<td>68%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 840 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们内部持股比例高的 840 只快速成长全球公司的完整名单。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在这里，我们重点介绍我们独家筛选器中的几家最爱。</p>
</div><h2>3Peak (SHSE:688536)</h2>
<div class="lb-trans"><h2>3Peak（上交所：688536）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> 3Peak Incorporated focuses on the research, development, and sale of analog integrated circuit products both in China and internationally, with a market cap of CN¥19.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 3Peak Incorporated 专注于模拟集成电路产品的研发和销售，业务覆盖中国及国际市场，市值为 190.6 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥1.44 billion from its operations in the integrated circuit industry.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司在集成电路行业的运营收入为 14.4 亿人民币。</p>
</div><p><strong>Insider Ownership:</strong> 14.2%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 14.2%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 26.6% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 年均 26.6%。</p>
</div><p>3Peak's revenue is projected to grow significantly at 26.6% annually, outpacing the Chinese market's average growth rate. The company recently reported a turnaround with a net income of CNY 15.56 million for Q1 2025, compared to a loss the previous year. Despite high volatility in its share price and low forecasted return on equity, it's expected to achieve profitability within three years, reflecting strong growth potential amid stable insider ownership dynamics.</p>
<div class="lb-trans"><p>3Peak 的收入预计将显著增长，年均增长 26.6%，超过中国市场的平均增长率。公司最近报告了扭亏为盈，2025 年第一季度净收入为 1556 万人民币，而去年则出现亏损。尽管其股价波动性较高，且预计股本回报率较低，但预计将在三年内实现盈利，反映出在稳定的内部持股动态下强劲的增长潜力。</p>
</div><ul>
<li>Get an in-depth perspective on 3Peak's performance by reading our analyst estimates report here.</li>
<li>Our valuation report unveils the possibility 3Peak's shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解 3Peak 的表现。</li>
<li>我们的估值报告揭示了 3Peak 的股票可能以溢价交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4f33f209-075c-4e96-ac20-46f7ba1204f6/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688536 Earnings and Revenue Growth as at Jun 2025</p>
<div class="lb-trans"><p>上交所：688536 截至 2025 年 6 月的收益和收入增长</p>
</div><h2>Qi An Xin Technology Group (SHSE:688561)</h2>
<div class="lb-trans"><h2>奇安信科技集团（上交所：688561）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Qi An Xin Technology Group Inc. is a cybersecurity company offering products and services to government, enterprises, and other institutions in China and internationally, with a market cap of CN¥20.58 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 奇安信科技集团有限公司是一家网络安全公司，向中国及国际的政府、企业和其他机构提供产品和服务，市值为 205.8 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue from the Information Security Industry segment, amounting to CN¥4.33 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司在信息安全行业的收入为 43.3 亿人民币。</p>
</div><p><strong>Insider Ownership:</strong> 22%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 22%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 19.3% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 年均 19.3%。</p>
</div><p>Qi An Xin Technology Group is poised for growth with revenue expected to increase at 19.3% annually, surpassing the Chinese market's average. Despite a net loss of CNY 417.68 million in Q1 2025, the company is forecasted to become profitable within three years, indicating robust growth potential. It trades at a significant discount to its estimated fair value and recently announced a CNY 300 million private placement, pending shareholder approval, suggesting strategic financial maneuvers amidst stable insider ownership.</p>
<div class="lb-trans"><p>奇安信科技集团有望实现增长，预计收入年均增长 19.3%，超过中国市场的平均水平。尽管 2025 年第一季度净亏损为 4.1768 亿人民币，但预计公司将在三年内实现盈利，显示出强劲的增长潜力。其股票以显著折扣交易于估计公允价值，并且最近宣布了一项 3 亿人民币的私募配售，待股东批准，这表明在稳定的内部持股下进行战略财务操作。</p>
</div><ul>
<li>Click here to discover the nuances of Qi An Xin Technology Group with our detailed analytical future growth report.</li>
<li>In light of our recent valuation report, it seems possible that Qi An Xin Technology Group is trading behind its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解奇安信科技集团的细微差别，查看我们的详细分析未来增长报告。</li>
<li>根据我们最近的估值报告，奇安信科技集团的股票似乎低于其估计价值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/aabf5e41-e45f-4e0e-b547-15bab0c91da9/chart/ownership-breakdown"/></p>
<p>SHSE:688561 Ownership Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>上交所：688561 截至 2025 年 6 月的持股结构</p>
</div><h2>Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)</h2>
<div class="lb-trans"><h2>浙江佐力药业（深交所：300181）</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Zhejiang Jolly Pharmaceutical Co., LTD is involved in the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥11.11 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 浙江佐力药业有限公司从事中药产品的研发、生产和营销，业务覆盖国内外，市值为 111.1 亿人民币。</p>
</div><p><strong>Operations:</strong> Zhejiang Jolly Pharmaceutical Co., LTD generates its revenue primarily through the research, production, and marketing of Chinese medicinal products in both domestic and international markets.</p>
<div class="lb-trans"><p><strong>运营：</strong> 浙江佐力药业有限公司主要通过中药产品的研发、生产和营销在国内外市场产生收入。</p>
</div><p><strong>Insider Ownership:</strong> 23.1%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 23.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 20.4% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 年均 20.4%。</p>
</div><p>Zhejiang Jolly Pharmaceutical shows promising growth with revenue expected to rise 20.4% annually, outpacing the Chinese market. Despite a dividend yield of 3.38% not fully covered by free cash flows, the company trades at a good value compared to peers and is priced significantly below its estimated fair value. Recent earnings reports indicate strong financial performance with increased sales and net income year-over-year, while insider ownership remains stable without substantial recent trading activity.</p>
<div class="lb-trans"><p>浙江佐力药业显示出良好的增长前景，预计收入年均增长 20.4%，超过中国市场。尽管其 3.38% 的股息收益率未完全由自由现金流覆盖，但与同行相比，该公司以良好的价值交易，且价格显著低于其估计公允价值。最近的财报显示出强劲的财务表现，销售和净收入同比增长，而内部持股保持稳定，近期没有重大交易活动。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Zhejiang Jolly PharmaceuticalLTD's earnings growth report.</li>
<li>The analysis detailed in our Zhejiang Jolly PharmaceuticalLTD valuation report hints at an deflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击以探索我们在浙江佐力药业收益增长报告中的详细发现。</li>
<li>我们的浙江佐力药业估值报告中的分析暗示其股价相较于估计价值被低估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300181 Earnings and Revenue Growth as at Jun 2025</p>
<div class="lb-trans"><p>深交所：300181 截至 2025 年 6 月的收益和收入增长</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该如何？</h2>
</div><ul>
<li>Click here to access our complete index of 840 Fast Growing Global Companies With High Insider Ownership.</li>
<li>Seeking Other Investments? Uncover 19 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们 840 家快速成长全球公司内部持股比例高的完整索引。</li>
<li>寻找其他投资？发现 19 家在 COVID 后生存并蓬勃发展的公司，具备应对特朗普关税的正确条件。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

由内部人士持股的成长型公司在 2025 年 6 月引领全球市场